NEW YORK, Jan 8 – In two separate agreements, Incyte has licensed its portfolio of gene patents and sequence information to both Agilent and Corning for use in their microarrays, Incyte announced Monday.
In the Corning agreement, the fiber-optics giant will have access to Incyte’s LifeSeq Gold human gene sequence database as well as Incyte’s ZooSeq animal database so it can manufacture human and animal genome microarrays. Corning’s microarray users will be able to click through on Incyte's website to Incyte’s database to buy additional genetic information as needed. Incyte will receive royalties on the sale of microarrays that Corning develops using this technology and databases.
Further financial terms of the deal were not disclosed.
“We believe this agreement will significantly enhance our ability to design and produce microarrays, and continues to strengthen our genetic content access supporting our planned full commercial microarray production in 2001,” Thomas Hinman, vice president of Corning Microarray technologies, said in a statement.
The Agilent agreement is substantially similar. Agilent has licensed Incyte’s cDNA clone sets in making animal and human gene expression microarrays. Researchers will have click-through access to Incyte’s LifeSeq gene-by-gene site so they can purchase additional information on specific genes. Incyte will also receive royalties from the sale of these arrays.
While Agilent already has custom oligonucleotide microarrays and other gene expression analysis tools on the market, Corning is a relative latecomer to the microarray market, having begun an effort in September to use its high-volume manufacturing processes to develop microarrays. In October, Corning completed a $10 million four-year agreement with MIT’s Whitehead Institute to develop the microarrays.
Incyte has entered into similar licensing agreements with two other microarray makers. It licensed its database of gene patents to Motorola, and its cDNA clones to PerkinElmer for commercialization of microarrays. In both agreements, Incyte is to receive royalties on the sale of microarrays.